Castle Biosciences projects $287-$297M revenue for 2025 amid strategic acquisitions and growth initiatives
Source: SeekingAlpha
2025-05-06 13:39:30 ET
More on Castle Biosciences
- Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript
- Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern
- Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript
- Castle Biosciences Non-GAAP EPS of -$0.20 misses by $0.13, revenue of $87.99M beats by $7.61M
- Castle Biosciences Q1 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Castle Biosciences projects $287-$297M revenue for 2025 amid strategic acquisitions and growth initiatives
Castle Biosciences Inc.
NASDAQ: CSTL
CSTL Trading
1.08% G/L:
$25.32 Last:
82,523 Volume:
$25.40 Open:
CSTL Latest News
March 13, 2026 11:02:12 am
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
March 09, 2026 07:00:00 am
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
March 04, 2026 04:30:00 pm
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB
March 03, 2026 04:30:00 pm
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
CSTL Stock Data
$948,047,644
27,291,396
0.3%
60
N/A
Medical Diagnostics & Screening
Healthcare
US
Friendswood
